The Hastings Center, Garrison, NY 10524, USA.
Child Adolesc Psychiatry Ment Health. 2010 Mar 10;4:9. doi: 10.1186/1753-2000-4-9.
This commentary grows out of an interdisciplinary workshop focused on controversies surrounding the diagnosis and treatment of bipolar disorder (BP) in children. Although debate about the occurrence and frequency of BP in children is more than 50 years old, it increased in the mid 1990s when researchers adapted the DSM account of bipolar symptoms to diagnose children. We offer a brief history of the debate from the mid 90s through the present, ending with current efforts to distinguish between a small number of children whose behaviors closely fit DSM criteria for BP, and a significantly larger number of children who have been receiving a BP diagnosis but whose behaviors do not closely fit those criteria. We agree with one emerging approach, which gives part or all of that larger number of children a new diagnosis called Severe Mood Dysregulation or Temper Dysregulation Disorder with Dysphoria.Three major concerns arose about interpreting the DSM criteria more loosely in children than in adults. If clinicians offer a treatment for disorder A, but the patient has disorder B, treatment may be compromised. Because DSM's diagnostic labels are meant to facilitate research, when they are applied inconsistently, such research is compromised. And because BP has a strong genetic component, the label can distract attention from the family or social context.Once a BP diagnosis is made, concerns remain regarding the primary, pharmacological mode of treatment: data supporting the efficacy of the often complex regimens are weak and side effects can be significant. However, more than is widely appreciated, data do support the efficacy of the psychosocial treatments that should accompany pharmacotherapy. Physicians, educators, and families should adopt a multimodal approach, which focuses as much on the child's context as on her body. If physicians are to fulfill their ethical obligation to facilitate truly informed consent, they must be forthcoming with families about the relevant uncertainties and complexities.
这篇评论源于一个跨学科研讨会,重点讨论了围绕儿童双相情感障碍(BP)诊断和治疗的争议。尽管关于儿童 BP 的发生和频率的争论已经超过 50 年,但在 20 世纪 90 年代中期,当研究人员将 DSM 中双相症状的描述应用于诊断儿童时,这种争论有所增加。我们提供了从中期 90 年代到现在的辩论简史,最后是当前区分少数行为与 DSM 中 BP 标准密切吻合的儿童,以及数量明显更多的儿童的努力,他们已经被诊断为 BP,但行为与这些标准不太吻合。我们同意一种新兴的方法,即给那部分或全部的更大数量的儿童一个新的诊断,称为严重情绪失调或伴有烦躁的情绪调节障碍。
关于在儿童中比在成人中更宽松地解释 DSM 标准有三个主要关注点。如果临床医生为疾病 A 提供治疗,但患者患有疾病 B,那么治疗可能会受到影响。由于 DSM 的诊断标签旨在促进研究,因此当它们的应用不一致时,这样的研究就会受到影响。而且,由于 BP 具有很强的遗传成分,该标签会分散对家庭或社会环境的注意力。
一旦做出 BP 诊断,仍存在关于主要的药物治疗模式的担忧:支持经常复杂治疗方案疗效的数据很薄弱,副作用可能很明显。然而,比人们普遍认识到的更重要的是,数据确实支持了应伴随药物治疗的心理社会治疗的疗效。医生、教育者和家庭应该采取多模式方法,既要关注孩子的背景,也要关注她的身体。如果医生要履行他们促进真正知情同意的道德义务,他们就必须向家庭坦诚地说明相关的不确定性和复杂性。